128 related articles for article (PubMed ID: 26126695)
21. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
[TBL] [Abstract][Full Text] [Related]
22. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.
Schick U; Jorcano S; Nouet P; Rouzaud M; Vees H; Zilli T; Ratib O; Weber DC; Miralbell R
Acta Oncol; 2013 Nov; 52(8):1622-8. PubMed ID: 23544357
[TBL] [Abstract][Full Text] [Related]
23. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.
Wright JL; Black PC; Brown GA; Porter MP; Kamat AM; Dinney CP; Lin DW
J Urol; 2007 Dec; 178(6):2302-6; discussion 2307. PubMed ID: 17936803
[TBL] [Abstract][Full Text] [Related]
24. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study.
Rusthoven CG; Carlson JA; Waxweiler TV; Raben D; Dewitt PE; Crawford ED; Maroni PD; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1064-73. PubMed ID: 24661660
[TBL] [Abstract][Full Text] [Related]
25. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
Koppie TM; Grossfeld GD; Nudell DM; Weinberg VK; Carroll PR
J Urol; 2001 Jul; 166(1):111-5. PubMed ID: 11435834
[TBL] [Abstract][Full Text] [Related]
26. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
27. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial.
Poelaert F; Verbaeys C; Rappe B; Kimpe B; Billiet I; Plancke H; Decaestecker K; Fonteyne V; Buelens S; Lumen N
Urology; 2017 Aug; 106():146-152. PubMed ID: 28435034
[TBL] [Abstract][Full Text] [Related]
29. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
[TBL] [Abstract][Full Text] [Related]
30. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
[TBL] [Abstract][Full Text] [Related]
33. Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990.
Jones GW; Mettlin C; Murphy GP; Guinan P; Herr HW; Hussey DH; Chmiel JS; Fremgen AM; Clive RE; Zuber-Ocwieja KE
J Am Coll Surg; 1995 May; 180(5):545-54. PubMed ID: 7538405
[TBL] [Abstract][Full Text] [Related]
34. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology.
Barocas DA; Patel SG; Chang SS; Clark PE; Smith JA; Cookson MS
BJU Int; 2009 Oct; 104(8):1091-7. PubMed ID: 19389006
[TBL] [Abstract][Full Text] [Related]
36. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
37. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
38. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
[TBL] [Abstract][Full Text] [Related]
39. Seminal vesicle involvement at salvage radical prostatectomy.
Meeks JJ; Walker M; Bernstein M; Eastham JA
BJU Int; 2013 Jun; 111(8):E342-7. PubMed ID: 23495695
[TBL] [Abstract][Full Text] [Related]
40. Radical retropubic prostatectomy for prostate cancer with microscopic bladder neck involvement: survival and prognostic implications.
Villari D; Nesi G; Della Melina A; Palli D; Ceroti M; Castigli M; Filocamo MT; Li Marzi V; Nicita G
BJU Int; 2010 Apr; 105(7):946-50. PubMed ID: 19804424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
